Influenza

Over the past decade there has been a rise in hospitalisations and deaths due to influenza (flu). There are around 3500 deaths in Australia linked to the flu each year and 18,000 hospitalisations.

While vaccination can help prevent the flu, when patients with severe flu are admitted to hospital there are no effective drugs available to reduce the response to the virus.  Hudson Institute inflammation researchers are focusing on finding treatments to help these patients.

View Video | Associate Professor Michelle Tate and Dr Alison West outline the 2025 Flu Season

What is influenza?

Flu complications

How do you prevent the flu?

What are treatments for the flu?

Colds, flu and COVID-19 – are they linked?

Other viral disease research at Hudson Institute | Dengue and Zika viruses

Influenza research projects underway

Our leading scientific teams with expertise in inflammation, infection and immunity hold vital clues to help tackle deadly virus outbreaks. They are working to discover new treatments that can dampen damaging immune responses.

Treating severe influenza infections

Associate Professor Michelle Tate from the Viral Immunity and Immunopathology Research Group at Hudson Institute

Most people recover from the flu, but in some cases the immune system overacts, causing damaging inflammation and cell death in the lungs. This can lead to breathing difficulties, lung injury, and serious complications such as pneumonia or acute respiratory distress syndrome (ARDS).

The team lead by Associate Professor Michelle Tate investigates how influenza causes this harmful inflammation and why some people develop severe disease.

By identifying the steps that lead to this damaging response, we aim to develop new treatments that protect the lungs and reduce risk of severe illness. The Tate Lab is exploring targeted ways to stop influenza‑driven lung injury before it becomes life‑threatening.

Protecting against Zika virus infection

Influenza collaborators

Monash Health, Monash University, CSIRO, The University of Adelaide, University of Queensland, Griffith University, University of Bonn, German Centre for Neurodegenerative Diseases, University of Massachusetts Medical School, Peter Doherty Institute for Infection and Immunity, Commercial partners in the USA and Australia

Hudson Institute scientists cannot provide medical advice.

Share this page